Immunotherapy with ponezumab for probable cerebral amyloid angiopathy

OBJECTIVE: Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of β‐amyloid fragments leading to cerebrovascular dysfunction and other brain injuries. This phase 2, randomized, double–blind trial in patients with probable CAA assessed the efficacy and safety of ponezumab, a nov...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Clin Transl Neurol
Main Authors: Leurent, Claire, Goodman, James A., Zhang, Yao, He, Ping, Polimeni, Jonathan R., Gurol, Mahmut Edip, Lindsay, Monica, Frattura, Linda, Sohur, Usharbudh Shivraj, Viswanathan, Anand, Bednar, Martin M., Smith, Eric E., Greenberg, Steven M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469253/
https://ncbi.nlm.nih.gov/pubmed/31020004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.761
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados